Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label, Dose Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of Orally Administered CB-5083 in Subjects With Advanced Solid Tumors

NCT02243917 is registered in ClinicalTrials.gov with Cleave Biosciences, Inc. as lead sponsor.

NCT NCT02243917
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02243917 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label, Dose Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of Orally Administered CB-5083 in Subjects With Advanced Solid Tumors
Lead sponsor
Cleave Biosciences, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
October 11, 2014
Completion date
August 25, 2017
Enrollment
62 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors